Bind Therapeutics, currently developing a nanotech delivery platform for cancer, raised $70.5 million in a public offering of 4,700,00 shares at $15 each. The company began trading Friday under the ticker symbol "BIND."
U.S. researchers have developed tiny wires made of spider silk and coated with carbon nanotubes that have potential medical device applications.
Directing cancer drugs to their target is a mainstay of the drug-delivery industry, and researchers in Australia and the U.K. may have found a way to enhance imaging of drugs' release at tumor sites, helping to target them where they lie.
The drug giant, which is in the process of renovating its R&D wing, has hired on the crafty Cambridge, MA-based biotech Bind Therapeutics to work on a kinase inhibitor nanotech drug for treating cancer.
Just a few months after inking a tie-up with Amgen, Bind Therapeutics has come back from the deal table with another marquee partner looking to use its nanoengineering platform to launch newly amped-up treatments into the clinic.
Analysts predict enormous gains in the nanotechnology drug delivery market for the next three years, according to a new report. But the good news comes with a hovering rain cloud, as safety concerns regarding nanomedicines may dampen a bright future.
Israeli drug-delivery company PolyPid has partnered with U.S.-based devicemaker MIS Implants Technologies to develop a dual polymer-lipid bone-healing technology specifically for dental use.
Researchers at the University of California, Los Angeles, have created what could be a new way to treat cancer, combining nanotechnology with a genetic kill switch.
Researchers at Australia's University of Queensland have developed a vaccine-delivery system that dispenses with needle and syringe.
Scientists have found a way to use nanotechnology to capture and release tumor cells circulating in the blood. They believe the technological breakthrough will enable what are known as circulating tumor cells to become powerful new diagnostic tools for cancer and cancer metastasis, offering a far kinder alternative than an invasive biopsy.